Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic...
Good news and even better volume today. We should see this build a base around $10 - $12. Earnings on the 29th should be interesting. VWAP rejected and momentum slowed down. Long $IPA. There is no way big pharma doesn't like this play.
With the formation of a bullish doji at the demand zone, the chances of a trend reversal from here, are high. View negated below demand zone close.
A company with over 10 years of consistent and constant growth, a wide coverage of products already on the market and... despite an excellent quarterly for a news or a trail .. boom .. It drops suddenly ? In my opinion this is sheer market madness, the sites I use as a reference for fundamental analysis confirm to me what I say, the company always be more than...
Novavax COVID-19 vaccine more than 90% effective in U.S trial according to Reuters. Despite positive news (which we do not trade), we will share with you our current view on Novavax. a) The price is inside a descending Wedge, and due to positive news, we are observing a bullish GAP, and we may see the price outside the Wedge pattern b) The general strategy...
4H don't know how I haven't posted this gem yet
$RAD At an important area of contention. I'll be watching closely for a break above. I'm liking the setup if it can close above resistance.
Bullish news on cancer research and a looming patent publish date ETA June 1st. Earnings suck but they're shedding debt notes maybe for a buyout? Heads up on breakouts (short sellers wet dream). Cups within cups within cups. Dunno, DYOR and not investment advice.
Auropharma looks good, sustaining 1025 levels, it could move 1056 levels in the near term.
-The company said that it has reached into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology. -PIRS went on to explain that the collaboration will enable it...
Alembic Pharma Ready To .... No matter where market will go...alembic Pharma will go up ...tgt 1250 in next three months
#Ucugen breaking out of the ascending triangle. - Trend continuation to 20.00 USD expected! - Ocugen Inc. is a biopharmaceutical company focused on the development, development and commercialization therapies for eye diseases. - Ocugen is developing a vaccine against COVID-19. - Number of employees: 15 people.
This is an Elliot Wave projection suggesting we've just completed Wave 2 of a standard 5 Up formation. Wave 2 is often a 0.5 or 0.618 pullback on Wave 1. Wave 3 is often related to Wave 1 by 1:1, 1:1.618, or 1:2.618 (don't ask me why). Wave 4 often pulls back to the .382 of Wave 3. Wave 5 is least reliable and may replicate Wave 1 when Wave 3 extends, or...
Bat harmonic pattern targets: AB=0.38 XA BC=0.38 AB tp1=1.6 BC=$9 tp2=2.6 BC=$25 tp3=0.88 XA=$68 Crab harmonic pattern targets: tp1=2.6 BC=$25 tp2=3.6 BC=$68 tp3=1.6 XA=$3385
Syndax Pharmaceuticals recently had POSITIVE interim data on their phase 2 study in SNDX-5613 for Leukemia. This data was positive as they saw a 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status. Out of 43 of patients evaluated, 31 were able to be used as for significant data. These two...
With a multi-year breakout and current pharma sector conditions, I believe it's going to outperform the sector. Disclaimer: for education purposes only not recommended for trade. can use both weekly and daily timeframe for getting the big picture. Check the notes points for further clarity #sunpharma
First of all, I am not an expert when it comes to pharmaceutical companies! Why did I pick Hepion Pharmaceuticals (@hepionpharma)? 1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1) 2. They came from a super high share price and are currently on a super low level 3. They are working on a product CRV431 (recently...